Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT2 | P31751 | 5/20 | 0.56 |
| ▸ | AKT1 | P31749 | 2/20 | 0.47 |
| ▸ | ROCK1 | Q13464 | 8/20 | 0.47 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.47 |
| ▸ | MYLK4 | Q86YV6 | 6/20 | 0.45 |
| ▸ | CTSV | O60911 | 1/20 | 0.42 |
| ▸ | CTSL | P07711 | 1/20 | 0.42 |
| ▸ | CTSB | P07858 | 1/20 | 0.42 |
| ▸ | CTSS | P25774 | 1/20 | 0.42 |
| ▸ | GPR142 | Q7Z601 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1977375 | 0.85 | AKT2 (0.68) | AKT2AKT1ROCK1ROCK2MYLK4 | |
| SCHEMBL13183845 | 0.82 | AKT2 (0.50) | AKT2AKT1ROCK1ROCK2CTSV | |
| SCHEMBL1977438 | 0.79 | CTSL (0.48) | AKT2AKT1ROCK1ROCK2CTSV | |
| SCHEMBL4689010 | 0.75 | AKT2 (0.53) | AKT2AKT1ROCK1ROCK2MYLK4 | |
| SCHEMBL3459757 | 0.73 | ROCK1 (0.55) | AKT2AKT1ROCK1ROCK2MYLK4 | |
| SCHEMBL10269974 | 0.73 | LOXL2 (0.50) | — | |
| SCHEMBL1978044 | 0.72 | AKT2 (1.00) | AKT2AKT1ROCK1ROCK2MYLK4 | |
| SCHEMBL15321244 | 0.72 | AKT2 (0.50) | AKT2AKT1ROCK1ROCK2 | |
| SCHEMBL1541691 | 0.72 | GABBR2 (0.53) | — | |
| SCHEMBL8810284 | 0.72 | GABBR2 (0.53) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8541461-B2 | Pharmaceutical combinations comprising pyrazole derivatives as protein kinase modulators | ASTEX THERAPEUTICS LIMITED (GB) | 2013-09-24 | — | — | US | claimed |
| US-8343953-B2 | Pharmaceutical compounds | ASTEX THERAPEUTICS LIMITED (GB) | 2013-01-01 | — | — | US | claimed |
| CN-1922148-B | Pyrazole derivatives as protein kinase modulators | ASTEX THERAPEUTICS LTD | 2012-03-21 | — | — | CN | claimed |
| US-20110144080-A1 | PYRAZOLE DERIVATIVES AS PROTEIN KINASE MODULATORS | ASTEX THERAPEUTICS LIMITED (GB) | 2011-06-16 | — | — | US | claimed |
| EP-1706385-B1 | PYRAZOLE DERIVATIVES AS PROTEIN KINASE MODULATORS | ASTEX THERAPEUTICS LTD (GB) | 2010-10-06 | — | — | EP | claimed |
| EP-2228369-A1 | Pyrazole derivatives as protein kinase modulators | Astex Therapeutics Ltd. (GB) | 2010-09-15 | — | — | EP | claimed |
| US-20100166699-A1 | PHARMACEUTICAL COMBINATIONS COMPRISING PYRAZOLE DERIVATIVES AS PROTEIN KINASE MODULATORS | ASTEX THERAPEUTICS LIMITED (GB) | 2010-07-01 | — | — | US | claimed |
| US-20100130464-A1 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2010-05-27 | — | — | US | claimed |
| EP-1933832-A2 | PHARMACEUTICAL COMBINATIONS COMPRISING PYRAZOLE DERIVATIVES AS PROTEIN KINASE MODULATORS | Astex Therapeutics Limited (GB) | 2008-06-25 | — | — | EP | claimed |
| EP-1902032-A1 | PHARMACEUTICAL COMPOUNDS | Astex Therapeutics Limited (GB) | 2008-03-26 | — | — | EP | claimed |
| CN-1922148-A | Pyrazole derivatives as protein kinase modulators | ASTEX THERAPEUTICS LTD (GB) | 2007-02-28 | — | — | CN | claimed |
| WO-2006136821-A1 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2006-12-28 | — | — | WO | claimed |
| WO-2006136837-A2 | PHARMACEUTICAL COMBINATIONS COMPRISING PYRAZOLE DERIVATIVES AS PROTEIN KINASE MODULATORS | ASTEX THERAPEUTICS LIMITED (GB) | 2006-12-28 | — | — | WO | claimed |
| EP-1706385-A1 | PYRAZOLE DERIVATIVES AS PROTEIN KINASE MODULATORS | Astex Therapeutics Limited (GB) | 2006-10-04 | — | — | EP | claimed |
| WO-2005061463-A1 | PYRAZOLE DERIVATIVES AS PROTEIN KINASE MODULATORS | ASTEX THERAPEUTICS LIMITED (GB) | 2005-07-07 | — | — | WO | claimed |
| US-20160250187-A1 | PYRAZOLE DERIVATIVES AS PROTEIN KINASE MODULATORS | ASTEX THERAPEUTICS LTD (GB) | 2016-09-01 | — | — | US | disclosed |
| US-20160250187-A1 | PYRAZOLE DERIVATIVES AS PROTEIN KINASE MODULATORS | ASTEX THERAPEUTICS LTD (GB) | 2016-09-01 | — | — | US | disclosed |
| WO-2006136821-A1 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2006-12-28 | — | — | WO | disclosed |
| EP-1706385-A1 | PYRAZOLE DERIVATIVES AS PROTEIN KINASE MODULATORS | Astex Therapeutics Limited (GB) | 2006-10-04 | — | — | EP | disclosed |
| WO-2005061463-A1 | PYRAZOLE DERIVATIVES AS PROTEIN KINASE MODULATORS | ASTEX THERAPEUTICS LIMITED (GB) | 2005-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144080-A1 | PYRAZOLE DERIVATIVES AS PROTEIN KINASE MODULATORS | GRK3, GRK2, NR0B2 | AKT2 124/4885AKT1 107/4885ROCK1 1919/4885 |
| US-20100130464-A1 | PHARMACEUTICAL COMPOUNDS | GRK3, GRK4, GRK2 | AKT2 37/4885AKT1 40/4885ROCK1 32/4885 |
| US-20100166699-A1 | PHARMACEUTICAL COMBINATIONS COMPRISING PYRAZOLE DERIVATIVES AS PROTEIN KINASE MODULATORS | GRK3, ERBB3, NCOA3 | AKT2 214/4885AKT1 199/4885ROCK1 2679/4885 |
| US-20160250187-A1 | PYRAZOLE DERIVATIVES AS PROTEIN KINASE MODULATORS | GRK3, GRK2, NR0B2 | AKT2 114/4885AKT1 91/4885ROCK1 1742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.